Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer. The investigator will also be studying the side effects (good and bad) of alternating chemotherapy with erlotinib on metastatic colorectal cancer.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of Erlotinib (Tarceva) Alternating With Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer With Molecular Correlates for p53 Pathway|
- Demonstrate safety and efficacy of sequencing chemotherapy with erlotinib in the second-line treatment for metastatic colorectal cancer. [ Time Frame: Two to six months ] [ Designated as safety issue: No ]
|Study Start Date:||March 2008|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.
Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage.
Other Name: Tarceva
Please refer to this study by its ClinicalTrials.gov identifier: NCT00642746
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|